Professor Martin Reck explaining the background for CheckMate 9LA-study and the effect of the combination of nivolumab and ipilimumab + 2 cycles of chemotherapy as first-line treatment of stage IV/recurrent non-small cell lung cancer.
MEST SETE MEDtalks
ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer Se hele webinar
The COVID-19 pandemic has changed the format of this year’s ASCO Annual Meeting. The conference ran from 29 – 31 May under the theme "Unite and Conquer: Accelerating Progress Together."